{"id":"NCT04016714","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-28","primaryCompletion":"2021-10-29","completion":"2021-10-29","firstPosted":"2019-07-11","resultsPosted":"2022-12-01","lastUpdate":"2023-05-06"},"enrollment":1191,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"DRUG","name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"type":"DRUG","name":"Prevenar 13™","otherNames":["Prevnar 13™"]},{"type":"DRUG","name":"Vaxelis™","otherNames":[]},{"type":"DRUG","name":"M-M-R®II","otherNames":["Measles, Mumps, and Rubella Virus Vaccine Live"]},{"type":"DRUG","name":"VARIVAX™","otherNames":["Varicella Vaccine Live"]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevenar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical study is to evaluate the safety and immunogenicity of a 3-dose schedule (2-dose primary series followed by a toddler dose) of pneumococcal conjugate vaccine (PCV) as one of the currently recommended schedules by the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on Immunizations and practiced in many countries.\n\nThe primary hypotheses are that V114 is non-inferior to Prevenar 13™ for the 13 shared serotypes based on response rates and on anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 days following Dose 3; that V114 is superior to Prevenar 13™ for the 2 serotypes unique to V114 based on the response rates and on anti-PnPs serotype-specific IgG GMCs at 30 days following Dose 3; and that Vaxelis™ administered concomitantly with V114 is non-inferior to Vaxelis™ administered concomitantly with Prevenar 13™ at 30 days following Dose 3 for each antigen included in Vaxelis™.","primaryOutcome":{"measure":"Percentage of Participants With a Solicited Injection-site Adverse Event","timeFrame":"Day 1 to Day 14 after each vaccination","effectByArm":[{"arm":"V114","deltaMin":60,"sd":null},{"arm":"Prevenar 13™","deltaMin":65.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.050"},{"comp":"OG000 vs OG001","p":"= 0.460"},{"comp":"OG000 vs OG001","p":"= 0.225"},{"comp":"OG000 vs OG001","p":"= 0.430"}]},"eligibility":{"minAge":"70 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":20},"locations":{"siteCount":24,"countries":["Denmark","Finland","Italy","Norway","Sweden"]},"refs":{"pmids":["36841723"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":595},"commonTop":["Irritability","Somnolence","Injection site erythema","Injection site pain","Injection site induration"]}}